China Biotech Industry Market Report and Forecast 2026-2034

Study Period

2021-2034

Market (2025)

USD 120.0 Billion

Market (2034)

USD 346.38 Billion

CAGR

12.5%

Major Markets Players

Jiangsu Hengrui, WuXi AppTec, BeOne Medicines, Innovent Biologics, Sino Biopharmaceutical and Others

*Note: Partial List Randomly Ordered

China Biotech Industry Market Key Highlights

China Biotech Industry Market Insights & Analysis

The China Biotech Industry Market is anticipated to register a CAGR of 12.5% during forecast period 2026-2034. The market size was valued at USD 120.0 billion in 2025 and is projected to reach USD 346.38 billion by 2034. China’s biotech industry has shifted from generics manufacturing toward innovation-led growth, supported by strong R&D investments and policy backing. By 2025, China accounted for over 30% of global clinical trials initiated annually, reflecting its rising role in global drug development. Investment in biotech exceeded USD 45 billion in 2024 alone, driven by venture capital, government funds, and public market financing. The country has also become a hub for antibody-drug conjugates (ADCs) and CAR-T therapies, with more than 120 cell therapy pipelines under development.

At the same time, global partnerships have reshaped the ecosystem. Chinese firms increasingly license molecules to multinational pharmaceutical companies, with deal values crossing USD 25 billion in 2025. Infrastructure expansion, such as high-capacity biologics manufacturing parks in Jiangsu and Shanghai, continues to scale production capabilities. This integrated growth—combining innovation, manufacturing, and commercialization- positions China as a central player in the global biotech landscape.

China Biotech Industry Market Dynamics

Key Driver: Rapid Expansion of Innovative Drug Pipelines

China’s biotech growth is strongly driven by its expanding innovative drug pipeline, particularly in oncology and immunology. By 2025, over 1,200 biologic drugs were in development, with oncology accounting for nearly 45% of total pipelines. The country has seen a sharp rise in first-in-class and best-in-class drug candidates, signaling a shift toward innovation rather than replication.

This expansion is closely tied to increasing R&D spending, which grew at an annual rate above 18% over the past five years. Companies are focusing on complex modalities such as bispecific antibodies and gene-editing therapies. As a result, China is not only addressing domestic healthcare needs but also becoming a global exporter of innovative therapies.

Industry Trends: Rise of Advanced Biologics and AI-Driven Discovery

The industry is witnessing rapid adoption of advanced biologics such as ADCs, mRNA platforms, and gene therapies. By 2025, China had over 70 ADC candidates in clinical stages, making it one of the fastest-growing segments. These therapies offer targeted treatment with improved efficacy, especially in cancer care.

Alongside this, AI-driven drug discovery is gaining traction. Companies are using machine learning to reduce early-stage drug discovery timelines by nearly 30%. This combination of biological innovation and digital tools is reshaping development cycles and improving success rates across clinical phases.

Major Challenge: Regulatory Complexity and Global Compliance Barriers

While regulatory reforms have improved approval timelines, navigating both domestic and international regulatory frameworks remains complex. For companies aiming for global expansion, meeting FDA and EMA standards requires significant investment in clinical validation and compliance.

In addition, variations in intellectual property protection and data transparency create hurdles for cross-border collaborations. Smaller biotech firms often struggle to scale globally due to these compliance demands, which can delay product launches and increase operational costs.

Opportunity: Expansion into Global Markets through Licensing and Partnerships

Chinese biotech firms are increasingly leveraging out-licensing and co-development deals to access global markets. In 2025, cross-border licensing deals involving Chinese biotech assets grew by over 35%, reflecting strong international demand for innovative molecules.

This trend is further supported by improving clinical data quality and regulatory alignment. As more Chinese therapies gain approval in global markets, companies can expand revenue streams while reducing commercialization risks. This creates a strong pathway for sustained long-term growth.

China Biotech Industry Market Segment-wise Analysis

By Technology:

• Biopharmaceuticals
• Vaccines
• Genomics and Molecular Diagnostics
• Contract Development and Manufacturing
• Clinical Research and CRO

The biopharmaceuticals segment leads the market with around 42% share, driven by high demand for monoclonal antibodies and recombinant proteins. China has over 300 monoclonal antibody drugs in development, reflecting strong innovation in targeted therapies. Oncology biologics alone contribute nearly 50% of this segment’s revenue, supported by rising cancer incidence and increasing adoption of biologic treatments.

In addition, biosimilars have gained strong traction due to cost advantages, accounting for nearly 28% of biologics sales. Domestic companies are focusing on scaling production capacity and improving quality standards to compete globally. This has positioned China as a key supplier of biologics across emerging markets.

By Product:

• Therapeutic Biologics
• Vaccines Portfolio
• Diagnostics and Genomics Products
• Cell and Gene Therapy Products
• Biotech Platforms and Services

Therapeutic biologics dominate the product segment with nearly 46% revenue share, largely due to increasing demand for oncology and immunology treatments. By 2025, biologic drugs represented over 35% of total pharmaceutical sales in China, highlighting their growing importance.

The segment is further supported by strong clinical pipelines and rising healthcare expenditure. CAR-T therapies and gene-edited treatments are also gaining traction, with more than 20 products in late-stage trials. This continuous innovation is expected to sustain segment dominance over the forecast period.

Regional Projection of China Biotech Industry

• East
• North
• Northeast
• South Central
• Southwest
• Northwest

The East region leads the China biotech industry with around 39% market share, driven by strong industrial infrastructure and R&D ecosystems in cities like Shanghai and Jiangsu. These regions host major biotech parks, accounting for over 60% of the country’s biologics manufacturing capacity.

Additionally, government support and access to global capital markets have accelerated innovation in this region. The presence of leading companies and research institutes fosters collaboration and rapid commercialization. This makes the East region a central hub for biotech development and export growth.

Government Initiatives & Policies

• China Bioeconomy Development Plan (14th Five-Year Plan): Focuses on accelerating biotech innovation, biopharma manufacturing, and genomic research expansion.
• NMPA Accelerated Drug Approval Reform (Updated 2025): Enhances fast-track approvals for innovative biologics, oncology drugs, and rare disease therapies.

China Biotech Industry Market Recent Developments

• 2025: Jiangsu Hengrui reported strong financial growth with revenue reaching RMB 15.76 billion, supported by new drug approvals, multiple NDA filings, and an expanding oncology-focused pipeline.
• 2025: Innovent Biologics expanded its portfolio to 16 marketed products and strengthened global presence through strategic licensing agreements and late-stage clinical advancements.
• 2025: WuXi Biologics added 86 new development projects in H1 2025, significantly expanding its biologics pipeline and reinforcing its leadership in CDMO services.
• 2025: Zai Lab reported 22% revenue growth and advanced key oncology assets into late-stage trials, strengthening its innovation-driven growth strategy.
• 2025: Junshi Biosciences accelerated development of next-generation immunotherapies, expanding its global clinical footprint and reinforcing its oncology leadership.

Why Choose This Report?

• Provides a comprehensive overview of the overall market analysis, encompassing key trends, consumer behavior analysis, and risk assessment to support strategic decision-making.
• Provides accurate, up-to-date insights into market size, segmentation, and emerging opportunities, helping to minimize risk & capitalizing on growth.
• Gives deep understanding of target audience preferences, investment habits, and communication channels for enhanced product development & marketing effectiveness.
• Delivers competitive analysis & benchmarking, uncovering the strengths & weaknesses of market competitors to guide strategies.
• Consolidate comprehensive market intelligence, reducing reasoning & streamlining research efforts.
• Facilitates customized market segmentation & risk mitigation strategies, fine-tuned to the business objectives.
• Aids in identifying both market challenges & untapped opportunities within the industry to drive long-term business growth.
• Provides valuable information based on actual customer data & search trends.